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ABSTRACT 
The aim of the study was to prepare site specific drug delivery of flurbiprofen using polysaccharides by the formation of glycosidic linkage which 
is hydrolysed by the microflora present in colon. This approach prevents drug release in the upper gastrointestinal environment. Due to the 
minimal degradation of conjugates in upper Git, the in vitro drug release in SGF, SIF and SCF was found upto 4.26±0.03%, 12.41±0.08% and 
92.72±3.33% respectively. 
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Colon specific drug delivery technologies (CSDDT) are being 
enormously improved in current years. The major 
impediments in drug targeting to the colon are degradation 
pathways and systemic absorption of the drugs in the upper 
GI tract. Many research studies are being done in CSDDT to 
meet the needs of ever-increasing gastrointestinal 
complications such as Crohn’s disease and ulcerative colitis1-
3 amebic colitis 4-5, to treat colon cancer 6-9, to deliver the 
protein and peptide drugs10 and for the healing of ailments 
such as nocturnal asthma 11, 12, early morning arthritis 13,14, 
nocturnal angina 15 and hypertension 16 influenced by 
circadian rhythms. A range of strategies/systems have been 
developed/practiced for better colonic drug delivery. Among 
all other strategies, The traditional approaches for colon 
targeting are prodrug formulation, pH-sensitive drug 
delivery, time-dependent systems and microbial degradation 
methods to formulate different dosage forms like tablets, 
capsules, multiparticulates, microspheres, liposomes. . 
microbial degradation  system is more frequent and 
acceptable because A number of synthetic azo polymers and 
natural or modified polysaccharides (chondroitin sulphate, 
guar gum, xanthan gum, locust gum, inulin, dextrans, starch, 
amylose,pectins) degraded by the human colonic flora, have 
thus been investigated as colonic drug delivery carriers. The 
human colon has over 400 distinct species of bacteria as 
resident flora, a possible population of upto millionsof 
bacteria per gram of colonic contents. Among the reactions 
carried out by these gut flora are azoreduction and 
enzymatic cleavage i.e. glycosides. These metabolic 
processes may be responsible for the metabolism of many 
anti-inflammatory drugs and may also be applied to colon 
targeted delivery of them. .These systems are designed to 
reduce/avoid the degradation and absorption of the drugs in 
the starting portion of the gastrointestinal tract and reduce 
side effects of drugs. In oral colon-specific drug delivery 
system, colon has a large amount of lymphoma tissue 
(facilitates direct absorption in to the blood), negligible 
brush boarder membrane activity, and much less pancreatic 
enzymatic activity as compared with the small intestine to 
treat local diseases associated with colon. Nonsteroidal anti 
inflammatory drugs (NSAIDs) are extensively used in the 
management of pain and inflammation associated with 
osteoarthritis, rheumatoid arthritis and ulcerative colitis. 
They also preferred for the management of inflammatory 
bowel disease and large intestine cancers 17,18. Flurbiprofen, 
a nonsteroidal anti-inflammatory drug, successfully used for 
the management of inflammation, pain associated with 
rheumatoid arthritis, was selected as a model drug. It has 
plasma half-life 3-6 h. Its high dose frequency is due to its 
shorter half-life 19. The polysaccharides as carrier of NSAIDs 
to target colon is much better approach by formation of 
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glycosidic conjugates. It is biocompatible, biodegradable, 
non-toxic and shows mucoadhesive properties as well. Due 
to its mucoadhesion nature, its residence time in the colon 
can be increased, which subsequently results in maximum 
bioavailability. Taking the above information into account, a 
study was designed for the preparation and characterization 
of flurbiprofen conjugates for the colon drug delivery 
system20. 
METHODS AND MATERIALS 
Materials 
Flurbiprofen selected for the project was procured as gift 
samples from FDC, Ltd, Mumbai ,Indi Polysaccarides like 
dextran was purchasd from Himdia, Mumbai, India; chitosan 
was obtained as gift sample from Centeral Institute of 
Fisherish Technology, Cochin, India. Pectin and Inulin was 
purchased from Loba Chemical Pvt. Ltd, Mumbai. All other 
chemical and reagent were used of analytical grade. 
Methods 
Preparation of Drug Conjugates21-23 
Chemical modification of flurbiprofen 
Reduction of flurbiprofen 
Flurbiprofen ( 0.03 mole) and LiAlH4 ( 0.03 mole) in diethyl 
ether were refluxed in a water bath for 2 hr, filtered, washed 
with 10 mL diethyl ether for three times and then finally 
washed with water, dried and purified by recrystallization 
using ethanol water. Yield 71%; M.P. 107-109 oC. 
Chlorination of the [2-(2-Fluorobiphenyl-4-yl)] 
Propenol: 
The compound [2-(2-Fluorobiphenyl-4-yl)propanol] ( 0.015 
mole) and thionyl chloride (1.6 mL, 0.015 mole) were mixed 
and allowed to get reacted in a round bottom flask at 0 oC for 
1 hr, refluxed for 2 hr and allowed to cool and poured on to 
ice cold water. The compound was washed with distilled 
water several times to remove any unreacted thionyl 
chloride, purified by recrystallization using ethanol-water 
and dried. Yield 62%; M.P. 120- 122 oC. 
Conjugation of modified naproxen with polysaccharides 
Synthesis of Dextran-Flurbiprofen Conjugate (DFl) 
The solution of  dextran  in 25 mL of DMF in a round bottom 
flask, [2-(2-Fluorobiphenyl-4-yl) 1- Chloro propane ( 0.008 
mole), mercuric bromide ( 0.008 mole) and yellow mercuric 
oxide ( 0.004 mole) were added and refluxed for 2 hr under 
stirring. The obtained suspension was filtered and the 
filtrate was dried in a rotatory vacuum evaporator at 80 °C; 
100 rpm; 400 mm Hg. The product was recrystallized using 
methanol–distilled water, filtered using Whatmann filter 
paper, washed with distilled water and then dried. Yield 
70%; M.P. 246-248°C. 
Synthesis of Pectin-Flurbiprofen Conjugate (PFl) 
The solution of pectin  in 25 mL DMF in a round bottom flask 
[2-(2-Fluorobiphenyl-4-yl) 1- Chloro propane ( 0.008 mole) 
was added slowly. Then mercuric bromide ( 0.008 mole) and 
yellow mercuric oxide ( 0.004 mole) were added, stirred and 
refluxed for 2-3 hr. The obtained suspension was filtered, 
dried in a rotatory vacuum evaporator at 75 oC; 100 rpm; 
300 mm Hg and recrystallized using methanol-distilled 
water. The product was filtered using Whatmann filter paper 
and dried. Yield 51%; M.P. 245-247 oC. 
 
Synthesis of Inulin-Flurbiprofen Conjugate (IFl) 
Inulin in minimum quantity of water was added to [2-(2-
Fluorobiphenyl-4-yl) 1- Chloro propane (2g; 0.008 mole) in 
25 mL DMF. Then mercuric bromide ( 0.008 moles) and 
yellow mercuric oxide ( 0.004 mole) were added, stirred and 
refluxed for 2-3 hr. The obtained suspension was filtered, 
dried in a rotatory vacuum evaporator at 90 oC; 100 rpm; 
400 mm Hg and recrystallized using methanol-distilled 
water. The product was filtered using Whatmann filter paper 
and dried. Yield 56%; M.P. 248-249 oC. 
Synthesis of Chitosan-Flurbiprofen Conjugate (CFl ) 
The chitosan  dissolved in minimum quantity of 2% glacial 
acetic acid, 25 mL DMF containing ( 0.008 mole) [2-(2-
Fluorobiphenyl-4-yl) 1- Chloro propane was added under 
stirring. Then mercuric bromide ( 0.008 mole) and yellow 
mercuric oxide ( 0.004 mole) were also added to the 
solution, stirred and refluxed for 2 hr and then finally stirred 
at room temperature for 12 hr. The obtained suspension was 
filtered, dried in a rotatory vacuum evaporator at 90 oC; 100 
rpm; 400 mm Hg and recrystallized using methanol-distilled 
water. The product was filtered using Whatmann filter paper 
and dried. Yield 52%; M.P. 254-256 oC. 
Characterization 
Thin Layer Chromatography (TLC): the purity of the 
compound was checked by TLC using silica gel G, suitable 
solvent systems and detecting agent; iodine vapors 
FT-IR and 1 HNMR : The IR spectrum of the synthesized 
conjugates was recorded on jasco V -530 FTIR in potassium 
bromide (anhydrous , IR grade).The  1 HNMR spectrum of 
conjugates was recorded in DMF , using a 1 HNMR Varian 
Mercury 300 Hz, with super conducting magnet. 
Swelling Study of Conjugates 24 
Accurately weighed amount of each of the conjugates (Wo) 
was dipped in the swelling medium SGF pH 1.2, SIF-1 pH 4.5, 
SIF-2 pH 6.8 and SCF pH 7.0. for 2 hr. At predetermined time 
intervals, the gel was removed from the swelling medium, 
blotted with filter paper to remove excess water from the gel 
surface, and the swollen hydrogels (W1) was weighed. The 






Where W1- the weight of the swollen gel 
Wo- the weight of the conjugate 
In-Vitro Drug Release Studies 
In-vitro drug release studies were carried out according to 
Sounders and Ellenbogen (1985)11 extraction techniques 
using USP dissolution test apparatus (apparatus 2). The 
dissolution studies were carried out in different dissolution 
medium (900 mL) including simulated colonic fluid 
(4.0%w/v), which was stirred at 100 rpm at 37±0.2 oC.25 
Samples were withdrawn periodically and compensated 
with an equal volume of fresh dissolution media. The drug 
content in the withdrawn samples was estimated 
spectrophotometrically at ʎmax 247 nm for conjugates of 
flurbiprofen. 
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In-Vivo Animal Study 26 
Ulcerogenic Activity 
The ulcerogenic activity was determined by the Rainsford's 
cold stress method, which is used to determine ulcerogenic 
potency of a drug at a ten times higher dose. Albino rats were 
distributed in healthy control, standard group and test 
groups. Doses of each of the synthesized compounds were 
first calculated on equimolar basis of pure drug and then 
were converted into ten times higher doses. Formulation of 
synthesized compounds and standard drug were 
administered orally. After oral administration of 5 mL of the 
aqueous drug suspensions (at 10 times the normal dose), the 
animals were stressed by exposure to -15° for 1 h. The 
animals were placed in separate cages, to ensure equal cold 
exposure. After 2 hrs of drug administration, the rats were 
sacrificed using isoflurane anaesthesia, the stomach and 
duodenum were dissected out of the body along with the 
first 5 cm of the intestine, then rinsed with saline and the 
contents of the stomach were emptied. The stomach and the 
intestine were then excised open along the greater curvature 
and gently wiped clean with a swap dripped in saline. The 
mucosal damage was examined grossly using a magnifier. A 
score for the ulcer was studies similar to pyloric ligation 
induced ulcer model.27 
Scoring of ulcer will be made as follows: 
Normal stomach/intestine........ (0.0) 
Red coloration...............................  (0.5) 
Spot ulcer......................................... (1.0) 
Hemorrhagic streak……….…….  (1.5) 
Ulcers................................................. (2.0) 
Perforation....................................... (3.0) 
Mean ulcer score for each animal will be expressed as ulcer 
index (UI): 
UI = (UN + US + UP) x 10-1 
UN = Average of number of ulcer per animal 
US = Average of severity score 
UP = Percentage of animal with ulcer 
Colonic edema study 
A section of  inflammed  colon of healthy control, colitis 
control, standard control and test control group on twelth 
day in TNBS induced animal model after treatment with 
flurbiprofen and its conjugates , was weighed then dried in 
an oven (80 oC) for 24 hr and then reweighed to determine 
the wet-to-dry weight ratio, an indicator of colon edema.27 
RESULT AND DISCUSSION 
TLC 
Reduced compound of Flurbiprofen [2-(2-Fluorobiphenyl-4-
yl)] Propenol, The purity of the compound was checked by 
the TLC using silica gel G, solvent system; n hexane: ethyl 
acetate: glacial acetic acid (6:3:1) detecting agent; iodine 
vapors. Only one spot was obtained Rf - 0.77. 
After chlorination of the [2-(2-Fluorobiphenyl-4-yl)] 
Propenol, The purity of the compound was checked by the 
TLC using silica gel G, solvent system; n hexane: ethyl 
acetate: glacial acetic acid (6:3:1), detecting agent; iodine 
vapors. Only one spot was obtained, Rf - 0.78. 
The purity of Dextran – Flurbiprofen Conjugate was checked 
by TLC using silica gel G, solvent system; methanol: acetic 
acid: water (4:1:2) detecting agent; iodine vapour. Only one 
spot was obtained, Rf - 0.69. The purity of Pectin – 
Flurbiprofen Conjugate was checked by TLC using silica gel G, 
solvent system; ethyl acetate: water (10:1), detecting agent; iodine 
vapors. Only one spot was obtained, Rf - 0.74. The purity of 
Inulin – Flurbiprofen Conjugate was checked TLC using silica 
gel G, solvent system; ethyl acetate: water (10:1), detecting 
agent, iodine vapors. Only one spot was obtained, Rf - 0.67. 
The purity of Chitosan- Flurbiprofen Conjugate  was checked 
by TLC using silica gel G, solvent system ethyl acetate: acetic 
acid: water (5:1:2), detecting agent, iodine vapors. Only one 
spot was obtained, Rf - 0.71. 
Structural elucidation 
Reduced compound of Flurbiprofen IR (KBr) spectrum: 
3422.62( OH str), 3072.43(CH str aromatic), 2941.35(CH str, 
aliphatic), 2823.61 (CH str, aliphatic),( 1602.07, 1584.34, 
1492, 1423.16,C=C str in benzene)  1071.17(C-F str)  cm-1. 
The disappearance of peak at 1710.21cm-1, and appearance 
of peak at 3422.62 cm-1 (m; OHstr), confirms that the carboxyl 
group has been reduced to methyl hydroxyl group. 1 HNMR; : 
δ(ppm): 1.47 (CH3,3H ,d), 2.1 (CH, 1H, q),   7.2 - 7.4 
(benzene,m), 4.6 (OH, 1H, s),  3.4(CH2, 2H, d). Chlorinated 
product of flurbiprofen ([2-(2-Fluorobiphenyl-4-yl) 1- 
Chloro propane) IR (KBr) spectrum: 3073.43(CH str 
aromatic), 2942.34(CH str, aliphatic), 2823.61(CH str, 
aliphatic),  (1602.6, 1582.34, 1490.25, 1420.16 C=C str in 
benzene)  , 1071.17 (C-F str) ,702(C-Cl str) (cm-1). IR: 702 cm-
1(C-Clstr), confirms the formation of chloro derivative of 
flurbiprofen. 1 H-NMR   (ppm): 1.47 (CH3, 3H, d), 2.1 (CH, 1H, 
q), 7.2 - 7.5 (benzene,m) 3.2(CH2, 2H, d). IR spectrum of 
Dextran – Flurbiprofen Conjugate was shown some 
characteristic peaks at 3462.73(m; OHstr), 3038.27(CH str 
aromatic), 2990.22(CH str, aliphatic), 2860.35(CH str, 
aliphatic),  (1606.81, 1590.52, 1548.80, 1487.8 C=C str in 
benzene)  , 1140.20(glycosidic linkage str), 1071.76(C-F str)  
(cm-1) IR: IR: The disappearance of Cl str peak at 702.63 cm-1 
and appearance of  peak at 1140.20cm-1 (m; characteristic 
peaks in glycoside); 1H NMR: 3.6 ppm (d) indicate formation 
of glycosidic bond between drug and polysaccharide. IR 
spectrum of Pectin – Flurbiprofen Conjugate was shown 
some characteristic peaks at 3454.70(m; OHstr), 3014.65(CH 
str aromatic), 2922.07(CH str, aliphatic), 2804.87(CH str, 
aliphatic),  1749.39(C=O str), (1610.52, 1564.23, 1487, 
1410.76 C=C str in benzene),  1116.76(glycosidic linkage str), 
1071.76(C-F str)   (cm-1) IR The disappearance of Cl str peak 
at 702.63 cm-1 and appearance of peak at 1116.76 cm-1 (m; 
characteristic peaks in glycoside); 1H NMR: 3.40 ppm (d) 
indicate formation of glycosidic bond between drug and 
polysaccharide. 
IR (KBr) spectrum of Inulin – Flurbiprofen Conjugate was 
shown some characteristic peaks at: 3508.41(m; OHstr), 
3014.65(CH str aromatic), 2922.07(CH str, aliphatic), 
2873.31(CH str, aliphatic),  (1608.53, 1595.09, 1533.37, 
1440.79 C=C str in benzene),  1178.15(glycosidic linkage str) 
1071.76(C-F str)    (cm-1 ) The disappearance of Cl str peak at 
702.63 cm-1 and appearance of peak at 1163.05 cm-1 (m; 
characteristic peaks in glycoside); 1H NMR: 3.52 ppm (d) 
indicate formation of glycosidic bond between drug and 
polysaccharide.  IR spectrum of Chitosan- Flurbiprofen 
Conjugate was shown some characteristic peaks at  
3538.31(m; OHstr),( 3390.31, 3308.67 NH str), 3014.65(CH 
str aromatic), 2922.07(CH str, aliphatic), 2849.39(CH str, 
aliphatic), ( 1602.81, 1523.18, 1470.79, 1407.351 C=C str in 
benzene),,  1193.91(glycosidic linkage str), 1071.76(C-F str)      
(cm-1) IR :The disappearance of Cl str peak at 702.63 cm-1 
and appearance of  peak at 1193.91 cm-1 (m; characteristic 
peaks in glycoside); 1H NMR: 3.6 ppm (d) indicate formation 
of glycosidic bond between drug and polysaccharide. 
Swelling Index: 
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Drug release from swellable conjugates depends on the 
degree of gelation, hydration, chain relaxation and erosion of 
the polymer. Swelling studies were performed in simulated 
fluids to evaluate drug release kinetics of DFl, PFl, IFl and CFl 
and 6.09±0.26, 4.81±0.19, 3.80±0.11and 2.81±0.08 swelling 
ratio were found respectively in SGF. Conjugates synthesized 
with dextran showed higher swelling than the conjugates 
with chitosan in SGF. DFl, PFl, IFl and CFl showed 8.06±0.34, 
7.45±0.29, 7.02±0.34and 4.09±0.18 swelling ratio 
respectively in SIF II .Drug conjugates with pectin and 
dextran showed higher swelling than conjugates with 
chitosan in SIF II.  DFl, PFl, IFl and CFl showed 7.19±0.32, 
6.09±0.24, 5.08±0.22and 3.89±0.15 swelling ratio 
respectively in SIF I. Swelling studies of drug conjugates with 
pectin and dextran showed higher swelling than conjugates 
with chitosan in SIF I. Swelling studies of the drug conjugate 
were also performed in SCF the swelling ratio 30.62±1.11, 
25.08±1.08, 27.14±1.12and 35.29±1.31were found in case 
DFl, PFl, IFl and CFl respectively .Drug conjugates with 
chitosan showed maximum swellability while conjugates 
with pectin showed minimum swellability in SCF. 
 
Table 1:  Swelling Ratio of the Synthesized Conjugates in Simulated Fluids 
Conjugates Simulated gastric fluid Simulated 





DFl 6.09±0.26 7.19±0.32 8.06±0.34 30.62±1.11 
PFl 4.81±0.19 6.09±0.24 7.45±0.29 25.08±1.08 
IFl 3.80±0.11 5.08±0.22 7.02±0.34 27.14±1.12 
CFl 2.81±0.08 3.89±0.15 4.09±0.18 35.29±1.31 
Values represent Mean ±SD, n=6 
In-Vitro Drug Release 
In-vitro drug release studies showed drug release upto 
4.26±0.03%in SGF, 12.41±0.08% in SIF and 
92.72±3.33%from conjugates in SCF which confirm the 
stability of drug conjugates in SGF and would have more 
potential for colon specific delivery. The initial drug release 
in SGF might be due to the fact that a small number of 
charges present in SGF might have allowed a faster drug 
release as a result of higher solvent penetration into the 
polymeric network. This would have resulted into a faster 
rate of polymer hydration in acidic pH of SGF. Once the outer 
layer is hydrated/gelled, it acts as a barrier for the drug 
release and the drug then slowly diffuses out independent of 
pH. The drug release in SIF I and SIF II could be attributed to 
the fact that there might be an ion exchange phenomenon 
between these fluids, but release of drug from conjugates in 
colon is due to presence of microfloral enzymes which 
degrade polysaccharide as well as hydrolysis of glycosidic 
linkage in conjugates. The results of this study revealed that 
the conjugates would be suitable for colonic delivery system 





Figure 1: Cumulative % drug release from conjugates
Colonic edema study 
A section of affected colon was weighed, dried in an oven (80 
oC) for 24 hr and then reweighed to determine the wet-to-
dry weight ratio, an indicator of colon edema .this 
pharmacological evaluation shows that the wet-to –dry 
weight ratio of animals of test groups was very close to 
healthy group. This study confirms better  anti-inflammatory 
activity of  conjugates as compared to parent drug .The 
Wet/dry weight ratio of Healthy ,Colitis control, Flurbiprofen 
, DFl, PFl,  IFl and CFl was 4.2±0.22, 6.4±0.23, 6.1±0.12, 
4.41±0.19, 5.09±0.21, 4.56±0.23and 4.28±0.17respectively. 
 
 
Table 2: Wet/Dry Weight Ratio of the Albino Rats Colon 
S. No. Groups Wet/dry weight ratio 
1 Healthy 4.2±0.22 
2 Colitis control 6.4±0.23 
3 Flurbiprofen 6.1±0.12 
4 DFl 4.41±0.19 
5 PFl 5.09±0.21 
6 IFl 4.56±0.23 
7 CFl 4.28±0.17 
Values represent mean± SD (n=6) 
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In-vivo ulcerogenic activity 
The ulcerogenic activity was determined by the Rainsford's 
cold stress method, which is used to determine ulcerogenic 
potency of a drug at a ten times higher dose. Albino rats were 
distributed in healthy control, standard group and test 
groups. Doses of each of the synthesized compounds were 
first calculated on equimolar basis of Flurbiprofen (10 mg 
/kg) and then were converted into ten times higher 
doses.The conjugates of drug shown very less ulcer index as 
compared to pure drug which were Healthy (2.12±0.57), 
Flurbiprofen (29.62 ±0.31), DFl (4.72±0.56), PFl (5.16±0.72), 
IFl (6.32±0.22) and CFl (3.21±0.51). 
Table 3: Ulcerogenic activity of drug/formulations 
S. No. Group Ulcer Index 
1 Healthy 2.12±0.57 
2 Flurbiprofen 29.62  ±0.31 
3 DFl 4.72±0.56 
4 PFl 5.16±0.72 
5 IFl 6.32±0.22 
6 CFl 3.21±0.51 
 
CONCLUSION 
The ileo-colonic region of the GIT has become an important 
site for drug targeting and drug absorption. Colon drug 
delivery system provides local and systemic treatment to the 
patients suffering from colon infections and colon diseases. 
However more commonly; systems that use natural 
materials that degraded by colonic bacterial enzymes are 
used now a days for ileo-colon specificity. Different diseases 
such as ulcerative colitis, colon cancer, and diarrhea can be 
treated by using delivery of drug through colon method and 
by this route different drugs of different nature and 
molecular weight can be administered effectively This 
method is good for poorly absorbed drugs because colon 
provides long retention time and shows good absorption. By 
comparing the dissolution data of test formulations and 
standard %age drug release was predicted. It was observed 
that release of drug in gastric media was minimum and it 
was also observed that release of drug in microbial media 
with phosphate buffer pH 7.0 was maximum. Conclusively an 
appropriate dosage form of conjugate can be considered as 
therapeutically efficacious system for treatment of colitis, 
with reduced gastric intolerance. 
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